Completing data — refresh the page later to see the latest
25122-41-2C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CClFCSHDIVRCWTZOX-DVTGEIKXSA-NClobetasol is a 3-oxo-1,4-steroid that is 16beta-methylpregna-1,4-diene-3,20-dione bearing hydroxy groups at the 11beta and 17alpha positions, fluorine at position 9, and a chlorine substituent at position 21. It is used as its 17alpha-propionate ester to treat various skin disorders, including exzema and psoriasis. It has a role as a SMO receptor agonist and an anti-inflammatory drug. It is a tertiary alpha-hydroxy ketone, a glucocorticoid, a 17alpha-hydroxy steroid, an 11beta-hydroxy steroid, a 20-oxo steroid, a fluorinated steroid, a 3-oxo-Delta(1),Delta(4)-steroid and a chlorinated steroid.
log Kow = 2.48
3
2.48
White to cream-colored crystalline powder /Clobetasol propionate/
White or or almost white colorless, crystalline powder, mp: 195.5-197 °C. Specific optical rotation: +103.8 deg at 25 °C/D (c = 1.04 in dioxane). UV max (ethanol): 237 nm (epsilon = 15000). Insoluble in water. /Clobetasol 17-propionate/
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
Danger
H360 (94.8%): May damage fertility or the unborn child [Danger Reproductive toxicity]
P203, P260, P273, P280, P318, P319, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 58 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
The Approved Drug Products with Therapeutic Equivalence Evaluations identifies currently marketed prescription drug products, including clobetasol propionate, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. /Clobetasol propionate/
Clobetasol propionate cream or ointment should be stored at 15-30 °C; the cream should not be refrigerated. Clobetasol propionate gel should be stored at 2-30 °C. Clobetasol propionate solution should be stored at 4-25 °C; the solution should not be used near an open flame. Clobetasol propionate lotion or shampoo should be stored at 20-25 °C; clobetasol propionate lotion should be protected from freezing. Clobetasol propionate foam should be stored at a controlled room temperature between 20-25 °C, and exposure to temperatures warmer than 49 °C should be avoided.
SRP: Expired or waste pharmaceuticals shall carefully take into consideration applicable DEA, EPA, and FDA regulations. It is not appropriate to dispose by flushing the pharmaceutical down the toilet or discarding to trash. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator.
D07AD01
D - Dermatologicals
S - Sensory organs
QD - Dermatologicals
QS - Sensory organs
Like other topical corticosteroids, clobetasol propionate has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.
ADN79D536H
CLOBETASOL
Established Pharmacologic Class [EPC] - Corticosteroid
Mechanisms of Action [MoA] - Corticosteroid Hormone Receptor Agonists
Clobetasol is a Corticosteroid. The mechanism of action of clobetasol is as a Corticosteroid Hormone Receptor Agonist.
Substances that reduce or suppress INFLAMMATION.
A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system.
Following topical application of clobetasol propionate to most areas of normal skin, only small amounts of the drug appear to reach the dermis and subsequently the systemic circulation with the usual dosage; however, systemic absorption may be increased when the usual dosage is exceeded or when the skin is inflamed or diseased. Mean peak plasma clobetasol propionate concentrations of 0.63 ng/mL occurred in one study 8 hours after a second 30-g dose (applied 13 hours after an initial dose) of clobetasol propionate 0.05% ointment in healthy individuals with normal skin; mean peak plasma concentrations of the drug were slightly higher and occurred 10 hours after the second dose when the 0.05% cream was employed. Mean peak plasma concentrations of approximately 2.3 or 4.6 ng/mL occurred in another study about 3 hours after a single application of a 25-g dose of a 0.05% ointment in patients with psoriasis or eczema, respectively.
25122-41-2、25122-46-7DTXSID2048955CHEMBL1201362CHEBI:205919SRP: At the time of review, regulatory criteria for small quantity disposal are subject to significant revision, however, household quantities of waste pharmaceuticals may be managed as follows: Mix with wet cat litter or coffee grounds, double bag in plastic, discard in trash.
TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 290(SRC), determined from a log Kow of 2.48(2) and a regression-derived equation(3), indicates that clobetasol is expected to have moderate mobility in soil(SRC). Volatilization of clobetasol from moist soil surfaces is not expected to be an important fate process(SRC) given an estimated Henry's Law constant of 1.6X10-10 atm-cu m/mole(SRC), using a fragment constant estimation method(4). Clobetasol is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 1.2X10-12 mm Hg at 25 °C(SRC), determined from a fragment constant method(5). Biodegradation data in soil were not available(SRC, 2011).
AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 290(SRC), determined from a log Kow of 2.48(2) and a regression-derived equation(3), indicates that clobetasol is expected to adsorb to suspended solids and sediment(SRC). Volatilization from water surfaces is not expected(4) based upon an estimated Henry's Law constant of 1.6X10-10 atm-cu m/mole(SRC), developed using a fragment constant estimation method(5). According to a classification scheme(6), an estimated BCF of 20(SRC), from its log Kow(2) and a regression-derived equation(3), suggests the potential for bioconcentration in aquatic organisms is low(SRC). Biodegradation data in water were not available(SRC, 2011).
ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), clobetasol, which has an estimated vapor pressure of 1.2X10-12 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), is expected to exist solely in the particulate phase in the ambient atmosphere. Particulate-phase clobetasol may be removed from the air by wet or dry deposition(SRC). Clobetasol does not contain chromophores that absorb at wavelengths >290 nm(4), and therefore is not expected to be susceptible to direct photolysis by sunlight(SRC).
The Koc of clobetasol is estimated as 290(SRC), using a log Kow of 2.48(1) and a regression-derived equation(2). According to a classification scheme(3), this estimated Koc value suggests that clobetasol is expected to have moderate mobility in soil.
/HUMAN EXPOSURE STUDIES/ The relatively rapid cutaneous restitution following cutaneous atrophy induced on the forearms of 4 volunteers (aged 20-34 yr) by continuous occlusive application of clobetasol propionate for 6 wk is described.
/CASE REPORTS/ The development of systemic side effects in a 55-yr-old woman with psoriasis after weekly topical application of 25 g clobetasol propionate (Dermovate; I), 0.05% diluted 1 in 4 in white soft paraffin and covering the treated area overnight with cling film, is reported. The patient had cushingoid facies, long, broad, purple striae spreading out onto the trunk and limbs from the groin and axillas, and atrophic plaques of steroid-suppressed psoriasis covering 15% of the trunk and limbs. Adrenal insufficiency developed when the dilution of I was increased to 1 in 16. It was concluded that transepidermal absorption of steroids will increase significantly if the skin is occluded with an impermeable film.
/CASE REPORTS/ A 60-yr-old woman with submammary intertrigo died after excessive topical application of 200 g clobetasol propionate 0.05% and 500 g of 1:4 dilution of the same preparation each week. Necropsy showed extensive venous thrombosis, particularly affecting the inferior vena cava. The kidneys showed tubular necrosis, secondary to the venous obstruction. Autopsy supported the diagnosis of iatrogenic Cushing's syndrome with consequent immobilization resulting in a fatal thrombosis.
/CASE REPORTS/ Four patients who used clobetasol propionate cream over a prolonged period; 3 patients used less than 50 g per week (7.5, 25 and 30 g per week) and yet all developed secondary adrenal failure for up to 4 months after cessation of therapy. Adrenal insufficiency following prolonged use of clobetasol propionate in moderate dosages may therefore be more common than previously recognized. It is suggested that the metyrapone test, which conveniently examines the entire HPA axis, should be employed in patients receiving long-term topical clobetasol propionate cream and that glucocorticoid supplementation should be given during episodes of stress, such as infections and surgery, for up to 4 months after cessation of therapy.
Drug-Induced Liver Injury Severity and Toxicity (DILIst)
Clobetasol
DILI Positive
DOI:10.1016/j.drudis.2019.09.022
An estimated BCF of 20 was calculated in fish for clobetasol(SRC), using a log Kow of 2.48(1) and a regression-derived equation(2). According to a classification scheme(3), this BCF suggests the potential for bioconcentration in aquatic organisms is low(SRC).
The Henry's Law constant for clobetasol is estimated as 1.6X10-10 atm-cu m/mole(SRC) using a fragment constant estimation method(1). This Henry's Law constant indicates that clobetasol is expected to be essentially nonvolatile from water and moist soil surfaces(2). Clobetasol is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 1.2X10-12 mm Hg(SRC), determined from a fragment constant method(3).
/LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ In rabbits, clobetasol propionate was teratogenic at doses of 3 and 10 ug/kg. These doses are approximately 0.001 and 0.003 times, respectively, the human topical dose of clobetasol propionate gel, cream and ointment. Abnormalities seen included cleft palate, cranioschisis, and other skeletal abnormalities. In rabbits, clobetasol propionate given by the same route was teratogenic at doses of 3 and 10 mcg/kg. These doses are approximately 0.001 and 0.003 times, respectively, the human topical dose of clobetasol propionate gel. Abnormalities seen included cleft palate, cranioschisis, and other skeletal abnormalities.
/LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ Clobetasol propionate has greater teratogenic potential than steroids that are less potent. Teratogenicity studies in mice using the subcutaneous route resulted in fetotoxicity at the highest dose tested (1 mg/kg) and teratogenicity at all dose levels tested down to 0.03 mg/kg. These doses are approximately 0.33 and 0.01 times, respectively, the human topical dose of clobetasol propionate gel, cream and ointment. Abnormalities seen included cleft palate and skeletal abnormalities.
/LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ Studies in the rat following oral administration /of clobetasol propionate/ at dosage levels up to 50 mg/kg per day revealed that the females exhibited an increase in the number of resorbed embryos and a decrease in the number of living fetuses at the highest dose.
/GENOTOXICITY/ Clobetasol propionate was non-mutagenic in three different test systems: the Ames test, the Saccharomyces cerevisiae gene conversion assay, and the Escherichia coli B WP2 fluctuation test
The rate constant for the vapor-phase reaction of clobetasol with photochemically-produced hydroxyl radicals has been estimated as 6.7X10-11 cu cm/molecule-sec at 25 °C(SRC) using a structure estimation method(1). This corresponds to an atmospheric half-life of about one hour at an atmospheric concentration of 5X10+5 hydroxyl radicals per cu cm(1). The rate constant for the vapor-phase reaction of clobetasol with ozone has been estimated as 1.3X10-17 cu cm/molecule-sec at 25 °C(SRC) that was derived using a structure estimation method(1). This corresponds to an atmospheric half-life of about 21 hours at an atmospheric concentration of 7X10+11 ozone molecules per cu cm(2). Clobetasol is not expected to undergo hydrolysis in the environment due to the lack of functional groups that hydrolyze under environmental conditions(3). Clobetasol does not contain chromophores that absorb at wavelengths >290 nm(3), and therefore is not expected to be susceptible to direct photolysis by sunlight(SRC).
Occupational exposure to clobetasol may occur through inhalation and dermal contact with this compound at workplaces where clobetasol is produced or used. Use data indicate that limited general population exposure will occur via ingestion of pharmaceutical products containing clobetasol. (SRC)
While data specific to clobetasol were not located(SRC, 2011), the literature suggests that some pharmaceutically active compounds originating from human and veterinary therapy are not eliminated completely in municipal sewage treatment plants and are therefore discharged into receiving waters(1). Wastewater treatment processes often were not designed to remove them from the effluent(2). Selected organic waste compounds may be degrading to new and more persistent compounds that may be released instead of or in addition to the parent compound(2).
Clobetasol's production and use as an anti-inflammatory may result in its release to the environment through various waste streams. If released to air, an estimated vapor pressure of 1.2X10-12 mm Hg at 25 °C indicates clobetasol will exist solely in the particulate phase in the atmosphere. Particulate-phase clobetasol will be removed from the atmosphere by wet or dry deposition. Clobetasol does not contain chromophores that absorb at wavelengths >290 nm, and therefore is not expected to be susceptible to direct photolysis by sunlight. If released to soil, clobetasol is expected to have moderate mobility based upon an estimated Koc of 290. Volatilization from moist soil surfaces is not expected to be an important fate process based upon an estimated Henry's Law constant of 1.6X10-10 atm-cu m/mole. Clobetasol may not volatilize from dry soil surfaces based upon its vapor pressure. If released into water, clobetasol is expected to adsorb to suspended solids and sediment based upon the estimated Koc. Volatilization from water surfaces is not expected to be an important fate process based upon this compound's estimated Henry's Law constant. An estimated BCF of 20 suggests the potential for bioconcentration in aquatic organisms is low. Hydrolysis is not expected to be an important environmental fate process since this compound lacks functional groups that hydrolyze under environmental conditions (pH 5 to 9). Occupational exposure to clobetasol may occur through inhalation and dermal contact with this compound at workplaces where clobetasol is produced or used. Use data indicate that limited general population exposure will occur via ingestion of pharmaceutical products containing clobetasol. (SRC)
The Approved Drug Products with Therapeutic Equivalence Evaluations identifies currently marketed prescription drug products, including clobetasol propionate, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. /Clobetasol propionate/
Percutaneous penetration of clobetasol propionate varies among individuals and can be altered by using different vehicles; results of in vitro studies using human skin indicate that absorption of topically applied clobetasol propionate gel is greater than that of topically applied clobetasol propionate cream. Percutaneous penetration can be increased by the use of occlusive dressings and by inflammation and/or other diseases of the epidermal barrier (e.g., psoriasis, eczema).
MEDICATION
Use (kg; approx.) in Germany (2009): >10
UsesClobetasol (Clobetasol Propionate EP Impurity G) is a topical corticosteroid. Glucocorticoid; anti-inflammatory.
UsesAtorvastatin Intermediate
DefinitionChEBI: A 3-oxo-Delta1,Delta4-steroid that is 16beta-methylpregna-1,4-diene-3,20-dione bearing hydroxy groups at the 11beta and 17alpha posit ons, fluorine at position 9, and a chlorine substituent at position 21. It is used as its 17alpha-propionate ester to treat various skin disorders, including exzema and psoriasis.